Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PPBT Relative to the S&P 500

PPBT Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Purple Biotech Ltd. (NASD:PPBT) seasonal charts above shows that a Buy Date of March 13 and a Sell Date of June 2 has resulted in a geometric average return of 4.36% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 59.93% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

To download PPBT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PPBT